XBiotech
XBIT
60 hedge funds and large institutions have $102M invested in XBiotech in 2019 Q4 according to their latest regulatory filings, with 19 funds opening new positions, 25 increasing their positions, 12 reducing their positions, and 6 closing their positions.
217% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 6
108% more repeat investments, than reductions
Existing positions increased: 25 | Existing positions reduced: 12
99% more capital invested
Capital invested by funds: $51.4M → $102M (+$50.8M)
28% more funds holding
Funds holding: 47 → 60 (+13)
1.34% more ownership
Funds ownership: 11.98% → 13.33% (+1.3%)
87% less call options, than puts
Call options by funds: $134K | Put options by funds: $1.05M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$6.22M |
| 2 |
D.E. Shaw & Co
New York
|
+$2.26M |
| 3 |
CAM
ClariVest Asset Management
San Diego,
California
|
+$2.09M |
| 4 |
Millennium Management
New York
|
+$1.57M |
| 5 |
Arrowstreet Capital
Boston,
Massachusetts
|
+$1.14M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BBA
Baker Bros. Advisors
New York
|
-$5.45M |
| 2 |
SI
Sofinnova Investments
Menlo Park,
California
|
-$1.52M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$1.3M |
| 4 |
6CM
683 Capital Management
New York
|
-$628K |
| 5 |
WG
Winton Group
London,
United Kingdom
|
-$356K |
XBIT Hedge Fund Activity: Q4 2019 in Review
60 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in XBiotech (XBIT) for Q4 2019, worth a combined $102M — up 99% from $51.4M a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new XBIT positions and 6 closed out — a net gain of 13 holders — while 25 added to existing stakes and 12 trimmed.
The largest buyer was BlackRock, adding an estimated $6.22M. The largest seller was Baker Bros. Advisors, exiting entirely with an estimated $5.45M sold.
- 60 institutional investors held XBiotech (XBIT) as of Q4 2019, up from 47 in Q3 2019.
- Funds reported $102M of XBiotech stock for Q4 2019, up 99% quarter-over-quarter.
- 19 funds opened new XBiotech positions in Q4 2019 and 6 closed out, a net change of +13 holders.
- The largest XBiotech buyer in Q4 2019 was BlackRock, an estimated $6.22M added.
- The largest XBiotech seller in Q4 2019 was Baker Bros. Advisors, an estimated $5.45M sold.
Based on aggregated 13F filings for Q4 2019.